Chemotherapy versus alectinib for the treatment of crizotinib-pretreated ALK-positive patients with non small cell lung cancer: A protocol for systematic review and meta-analysis

BACKGROUND: There are no evidence-based data in the literature to demonstrate that alectinib shows a clinically relevant advantage over chemotherapy in anaplastic lymphoma kinase-positive non-small cell lung cancer pretreated with crizotinib. Therefore, we designed this systematic review and meta-an...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ting, Li, Chenxi, He, Xiaopeng, Zhang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Study Protocol Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684200/
https://www.ncbi.nlm.nih.gov/pubmed/35356928
http://dx.doi.org/10.1097/MD.0000000000029064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684200/
https://www.ncbi.nlm.nih.gov/pubmed/35356928
http://dx.doi.org/10.1097/MD.0000000000029064

Ejemplares similares